Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKT1DA)

• Drug Name: MT-II Drug Info
• Synonyms: Melanotan II; 121062-08-6; Melanotan-II; Melanotan (MT)-II; Melatonan; Melanotan II acetate salt; CHEMBL430239; L-Lysinamide, N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-, cyclic (2-7)-peptide; (3S,6S,9R,12S,15S,23S)-12-((1H-imidazol-5-yl)methyl)-3-((1H-indol-3-yl)methyl)-15-((S)-2-acetamidohexanamido)-9-benzyl-6-(3-guanidinopropyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexaazacyclotricosane-23-carboxamide; Melanotan -Ii; C50H69N15O9; Asp5; Melanotan II acetate; D-Phe7; melanotan II; MTII; MTII Melanotan-II; Ac-Nle-c[Asp-His-DPhe-Arg-Trp-Lys]-NH2

Indication

Disease Entry	ICD 11	Status	REF
Female sexual arousal dysfunction	HA01.1	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 92432
  CAS Number: CAS 121062-08-6
  TTD Drug ID: DMKT1DA

Molecule-Related Drug Atlas

Drug(s) Targeting Melanocortin receptor 1 (MC1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[7]
Afamelanotide	DMVWHTG	Erythropoietic porphyrias	5C58.12	Approved	[8]
Dersimelagon	DMMO0SU	Erythropoietic protoporphyria	5C58.12	Phase 3	[9]
PL8177	DML5V22	Ulcerative colitis	DD71	Phase 2	[10]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[11]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	DMX7IVO	Discovery agent	N.A.	Investigative	[12]
Ac-YRMEHdFRWG-NH2	DMN2UKC	Discovery agent	N.A.	Investigative	[13]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	DMM19SJ	Discovery agent	N.A.	Investigative	[12]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	DMSIGJW	Discovery agent	N.A.	Investigative	[12]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	DMUESCH	Discovery agent	N.A.	Investigative	[12]

Drug(s) Targeting Melanocortin receptor (MCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-3291	DMBADQV	Ulcerative colitis	DD71	Phase 2	[14]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	DMX7IVO	Discovery agent	N.A.	Investigative	[12]
Ac-YRMEHdFRWG-NH2	DMN2UKC	Discovery agent	N.A.	Investigative	[13]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	DMM19SJ	Discovery agent	N.A.	Investigative	[12]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	DMSIGJW	Discovery agent	N.A.	Investigative	[12]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	DMUESCH	Discovery agent	N.A.	Investigative	[12]
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	DMVQ4KG	Discovery agent	N.A.	Investigative	[13]
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	DMD6OW4	Discovery agent	N.A.	Investigative	[15]
AEKKDEGPYRMEHFRWGSPPKD	DMZ8SV3	Discovery agent	N.A.	Investigative	[13]
Ac-YRMEHdFRWGSPPKD-NH2	DMDH5B3	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Melanocortin receptor 4 (MC4R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methylnaltrexone bromide	DMZTGN2	Opioid-induced constipation	DB32.1	Approved	[16]
Bremelanotide	DM20LIM	Hypoactive sexual desire dysfunction	HA00	Approved	[7]
Setmelanotide	DMPVRN9	Obesity	5B81	Approved	[17]
Amylin	DMWDEN0	N. A.	N. A.	Phase 4	[18]
AMG 386	DMQJXL4	Breast cancer	2C60-2C65	Phase 3	[16]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[19]
PF-446687	DML38VU	Female sexual arousal dysfunction	HA01.1	Phase 2	[20]
AP-1030	DMBGA35	Metabolic disorder	5C50-5D2Z	Phase 1/2	[11]
PF-07258669	DM3CJ5N	Malnutrition	5B50-5B71	Phase 1	[21]
PT-14	DMYM9JL	Erectile dysfunction	HA01.1	Discontinued in Phase 2	[22]

Drug(s) Targeting Melanocortin receptor 3 (MC3R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Melanotetan II	DMYK8MV	Obesity	5B81	Preclinical	[16]
C[Nle-Arg-D-Nal(2')-Arg-Trp-Glu]-NH2	DMX7IVO	Discovery agent	N.A.	Investigative	[12]
Ac-YRMEHdFRWG-NH2	DMN2UKC	Discovery agent	N.A.	Investigative	[13]
C[Nle-Gln-D-Nal(2')-Arg-Trp-Glu]-NH2	DMM19SJ	Discovery agent	N.A.	Investigative	[12]
C[Nle-Val-D-Nal(2')-Arg-Trp-Glu]-NH2	DMSIGJW	Discovery agent	N.A.	Investigative	[12]
C[Nle-Arg-D-Phe-Arg-Trp-Glu]-NH2	DMUESCH	Discovery agent	N.A.	Investigative	[12]
Ac-YR[CEH(d-2alpha-Nal)RWC]-NH2	DMVQ4KG	Discovery agent	N.A.	Investigative	[13]
C[CO-o-C6H4-CO-Pro-D-Nal(2)-Arg-Trp-Lys]-NH2	DMD6OW4	Discovery agent	N.A.	Investigative	[15]
AEKKDEGPYRMEHFRWGSPPKD	DMZ8SV3	Discovery agent	N.A.	Investigative	[13]
Ac-YRMEHdFRWGSPPKD-NH2	DMDH5B3	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Melanocortin receptor 5 (MC5R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MTC-896	DM7VG8L	Seborrhea	ED91.2	Phase 2	[23]
JNJ-10229570	DMY7Q3I	Acne vulgaris	ED80	Phase 2	[24]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Melanocortin receptor (MCR)	TTEOSZT	NOUNIPROTAC	Inhibitor	[2]
Melanocortin receptor 1 (MC1R)	TT0MV2T	MSHR_HUMAN	Agonist	[3]
Melanocortin receptor 3 (MC3R)	TTNI91K	MC3R_HUMAN	Agonist	[4]
Melanocortin receptor 4 (MC4R)	TTD0CIQ	MC4R_HUMAN	Agonist	[5]
Melanocortin receptor 5 (MC5R)	TT6QAJ3	MC5R_HUMAN	Agonist	[6]

References

• [1] Designing drugs for the treatment of female sexual dysfunction. Drug Discov Today. 2007 Sep;12(17-18):757-66.
• [2] Substitution of arginine with proline and proline derivatives in melanocyte-stimulating hormones leads to selectivity for human melanocortin 4 rece... J Med Chem. 2009 Jun 25;52(12):3627-35.
• [3] Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10. J Med Chem. 1989 Jan;32(1):174-9.
• [4] Characterization of melanocortin receptor ligands on cloned brain melanocortin receptors and on grooming behavior in the rat. Eur J Pharmacol. 1999 Aug 13;378(3):249-58.
• [5] Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry. 2000 Dec 5;39(48):14900-11.
• [6] The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur J Pharmacol. 2002 Apr 12;440(2-3):141-57.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [8] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [9] Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis. Arthritis Res Ther. 2022 Sep 1;24(1):210.
• [10] Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous Administration. Drugs R D. 2021 Dec;21(4):431-443.
• [11] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [12] Development of cyclic gamma-MSH analogues with selective hMC3R agonist and hMC3R/hMC5R antagonist activities. J Med Chem. 2006 Mar 23;49(6):1946-52.
• [13] Discovery of a beta-MSH-derived MC-4R selective agonist. J Med Chem. 2005 May 5;48(9):3095-8.
• [14] Clinical pipeline report, company report or official report of Drais Pharmaceuticals.
• [15] Structure-activity relationships of cyclic lactam analogues of alpha-melanocyte-stimulating hormone (alpha-MSH) targeting the human melanocortin-3 ... J Med Chem. 2008 Jan 24;51(2):187-95.
• [16] Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [18] Novel anti-obesity drugs. Expert Opin Investig Drugs. 2000 Jun;9(6):1317-26.
• [19] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [20] Melanocortin Receptor Agonists Facilitate Oxytocin-Dependent Partner Preference Formation in the Prairie Vole. Neuropsychopharmacology. 2015 Jul;40(8):1856-65.
• [21] Discovery of the Potent and Selective MC4R Antagonist PF-07258669 for the Potential Treatment of Appetite Loss. J Med Chem. 2023 Mar 9;66(5):3195-3211.
• [22] The protective effects of the melanocortin receptor (MCR) agonist, melanotan-II (MTII), against binge-like ethanol drinking are facilitated by deletion of the MC3 receptor in mice. Neuropeptides. 2014 Feb;48(1):47-51.
• [23] Clinical pipeline report, company report or official report of Avarx.
• [24] A melanocortin receptor 1 and 5 antagonist inhibits sebaceous gland differentiation and the production of sebum-specific lipids. J Dermatol Sci. 2011 Jul;63(1):23-32.